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INTRODUCTION 
 
                     Acute myocardial infarction is a life threatening condition. Sudden 
coronary artery occlusion leads to abrupt cessation of blood and oxygen flow to the 
heart muscle which in turn causes necrosis of the particular part of myocardium. The 
necrotic areas of heart muscles stops it contractile function. 
                     Lactotrophic cells of anterior pituitary synthesizes prolactin hormone. 
During acute coronary syndrome excess prolactin secreted via neuroendocrine stress 
pathway. Excess prolactin  may aggravate arteriosclerosis, augmentation of arterial 
stiffness and hypertension. 
                    Excess prolactin level  increases adhesion of the immune cells to 
endothelium through integrin‑mediated effects that may lead on to proliferation of 
vascular smooth muscle cells, which may produces atherosclerotic expansion and 
elevation of cardiac risk profile. 
                     Excess prolactin secreted via neuroendocrine stress pathway during 
acute coronary syndromes,  induces acute endothelial dysfunction, insulin resistance, 
and induction of vascular immune reactions, thus, prolonged  hyperprolactinemia  
plays a potential role in the development of ischemic cardiac diseases. 
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REVIEW OF  LITERATURE  
ATHEROSCLEROSIS – An Introduction 
                       Atherosclerosis is a chronic pathological process which damages 
coronary blood vessel and producing acute myocardial infarction. The patient may 
present with either ST elevation or Non ST elevation MI. Atherosclerotic plaques are 
susceptible to following pathologic changes with clinical significance:13 
 Rupture, Ulceration, or Erosion 
 Hemorrhage 
 Atheroembolism 
 Aneurysm formation 
PATHOGENESIS: 
Numerous pathogenic factors play potential role in the development of 
atherosclerosis11. Atherosclerosis is a disease of large and medium-sized muscular 
arteries and is characterized by2 – 
 Endothelial Dysfunction 
 Vascular Inflammation 
 Monocyte Adhesion to the endothelium 
 SMC Proliferations and ECM Production 
 Factor Release 
 Platelet Adhesion 
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 Deposition  of lipids, cholesterol, calcium, and cellular debris within the intima 
of the vessel wall 
 An Atheromatous plaque consisting of raised lesion with a soft, yellow, 
grumous core of lipid (mainly cholesterol and cholesterol esters) covered by a 
firm, white fibrouscap16. 
 
 
 Besides obstructing blood flow, atherosclerotic plaques weaken the underlying 
media and can themselves rupture, causing acute thrombosis 
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ENDOTHELIAL DYSFUNCTION 
                          Endothelium acts as a protective barrier between blood products and 
surface of vessel lumen. Endothelial injury is the initial triggering event in the 
development of atherosclerotic lesions inside the blood vessel lumen and there is 
decreased in NO {Nitrous Oxide} secretion and an increased releases of serotonin, 
thromboxane A2 and thrombin causing vasoconstriction or abnormal vasodilatation 
under vasoactive substances, at the site of the plaque which damage the endothelium. 
                          Other causes of  endothelial injury including  hemodynamic force, 
mechanical trauma, chemical and immunological mechanisms, metabolic agents like 
chronic hyperlipidemia, high level of  homocystine, circulating toxins from systemic 
infections, certain viruses, and tobacco products5. 
                        Beyond this, Endothelial injury is caused by diabetes, 
hypercholestrilemia, cigarette smoking, hypertension and high LDL. This can be 
prevented and controlled by life style modification, diet and drugs like ACE 
inhibitors, Statin, Flavonoids and Vitamin C. 
INFLAMMATION  
                         Inflammation plays potential role in genesis of atherosclerosis. 
During endothelial injury monocyte adheres to the endothelium, migrates and 
transform into macrophage. Then these macrophages engulf oxidized LDL 
cholesterol. Oxidized LDL produces modification in macrophage surface area which 
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release certain inflammatory substances like cytokines and growth factors. The 
important cytokines are intercellular adhesion molecule (ICAM-1), monocyte 
chemotactic protein (MCP-1), soluble CD4 ligand, macrophage and granulocyte-
macrophage colony stimulating factors. Interleukin IL-1, IL-3, IL-6, IL-8, IL-18 and 
TNF-Alpha5. They are all stimulate  atherogenesis. 
DYSLIPIDEMIA IN ATHEROSCLEROSIS 
         Lipid abnormalities play an important role in pathogenesis of 
atherosclerosis.  The atherosclerosis is accelerated by high cholesterol diet intake. 
The risk is increased if serum cholesterol is more than 150 mg/dl. It accelerates 
cholesterol deposition over blood vessels2. 
ROLE OF LIPOPROTEINS IN ATHEROSCLEROSIS  
 Important risk factor for atherosclerosis development is high LDL cholesterol 
and low levels of high density lipoprotein (HDL) . 
 LDL cholesterol engulfed by Macrophages. Inside the macrophages LDL 
undergoes oxidative modification. Because of these changes LDL-induced 
endothelial injury prevented. Accumulation of excess cholesterol in foam 
cells damage mitochondrium and induces apoptosis which releases 
chemokines, cytokines and prothrombotic molecules. 
 Endothelial cell surfaces are disrupted by oxidized LDL cholesterol. It 
releases cytokines and inflammatory substances from LDL engulfed 
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macrophages which accelerate accumulation of platelets. This unstabilised 
plaque and oxidized LDL levels are raised in acute coronary syndrome 
patients and directly correlate with the severity of symptoms2. 
 HDL cholesterol reverses atherogenesis by reverse cholesterol transport 
mechanism. It maintains the endothelial cell function and protect from 
thrombus formation. The longevity increased when serum HDL cholesterol 
more than 75mg/dl.  The Framingham Risk Assessment score gives negative 
risk factor for serum HDL more than 60 mg/dl. But there is no proven 
evidence to show increasing HDL cholesterol has reduces cardiovascular 
disease. 
 The apolipoprotein C3 belongs to triglyceride- rich lipoproteins which is 
more  atherogenic in nature. 
SMC PROLIFERATIONS AND ECM PRODUCTION. 
 Inflamed artery increases cholesterol plaque deposition which lead on to smooth 
muscle cells enlargement and form a hard cover over the affected area. Because of 
hard cover the artery becomes narrow and it reduces the blood flow and rises the  
blood pressure52 
HYPERTENSION 
                      Among many risk factor hypertension is one of the leading cause of 
atherosclerosis development. The coronary and cerebral circulatory vessels are 
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commonly affected. The important mechanism of hypertension is rising of arterial 
wall tension which damages the endothelium and produces development of fatty 
streaks2. 
SMOKING: 
In Genesis of atherosclerosis cigarette smoking is an important risk factor for   
endothelial damage which lead on to development of arterial thrombosis4.  
Following event happens while smoking 
 Cigarette smoke inhibits nitric oxide production. So, endothelium mediated 
vasodilator function  is affected. 
  Smoking rises interleukin-6, CRP,  and  TNF- alpha in both sexes. 
  Smoking reduces the accessibility of NO to platelets, so sensitivity of 
exogenous NO is reduced in platelets. This leads to increased platelet 
activation and adhesion, associated with raised serum fibrinogen and 
decreased fibrinolysis4. 
 Smoking augments the LDL oxidation, which lead on to atherosclerosis. 
DIABETES:  
                     Diabetes produce derangement of lipid profile lead on to dyslipidemia, 
excess insulin levels in serum predisposes to arterial diseases. Excess insulin acts on 
the macrophages and decreases ABCA – 1 and enhances the expression of CD 36, 
which lead on to cholesterol accumulation in the macrophages and monocyte surface 
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area. In general Cytokines like interleukin-6 (IL-6), MCP-1 and Oxidized LDL are 
raised in both Atherosclerosis and T2DM.34 Low grade inflammation is present in 
both. T2DM enhances atherosclerosis resulting in end organ damage. 
Lp-PLA2: 
Macrophages secrete the enzyme called Lipoprotein-associated phospholipase 
A2 (Lp-PLA2) which precipitates the plaque inflammatory surface. Its high level 
predict a 40 to 400 percent higher risk of myocardial infarction (MI). 
CYTOKINES: 
Most commonly encountered Cytokines in atherosclerosis are   interleukin-1 or 
Tumour Necrosis Factor-alpha. It increases the expression of many cell surface 
adhesion molecules such as, VCAM-1, ICAM-1, CD40L, CD40, and selectins.18 
These changes take place in  smooth muscle cells, endothelial cells and macrophages. 
Pro-inflammatory cytokines promote cell proliferation, release oxygen free radicals, 
stimulate MMP - 9, which induces the tissue factor expression. The antiatherogenic 
cytokines are IL-4 and IL-10.16 Interferon-gamma enhances the development of 
atherogenesis. 
LEUKOCYTE ACTIVATION: 
   In early stage of atherosclerosis inflammatory cells like Leukocyte 
(Monocytes and T lymphocytes) recruitment occurs in atherosclerosis site. which 
proving some evidence  systemic inflammatory reaction takes place in atherogenesis. 
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PREGNANCY-ASSOCIATED PLASMA PROTEIN-A (PAPP-A): 
  It is a zinc binding metalloproteinase enzyme. Atherosclerotic plaques 
surrounded by fibrous cap which prevent plaque rupture. PAPP-A degrades this 
fibrous cap and promotes plaque rupture. PAPP-A is secreted by fibroblasts, 
osteoblast, syncytiotrophoblast, endothelial, Macrophages/Monocyte and  blood 
vessel smooth muscle cells.33 PAPP-A is seen in ruptured atherosclerotic plaque not 
in stable plaque. 
DYSLIPIDEMIA: 
              The Important pathogenic hallmark of atherosclerosis is lipid abnormalities. 
High intake of cholesterol containing food accelerates atherosclerosis3. If serum 
cholesterol is > 150 mg/dl, the rate of atherosclerosis development is high .28 
TISSUE FACTOR: 
 Tissue factor is found in the atheromatous plaque along with other factors. 
Tissue factor initiates coagulation which leads on to thrombosis development. Tissue 
factor augments atherosclerosis via both coagulation-dependent and coagulation 
independent pathways. 
ANGIOTENSIN II: 
High level of Angiotensin II plays major role in atherogenesis. The level of 
Angiotensin II directly proportional to the severity of atherosclerosis. Tone of smooth 
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muscles in blood vessel are modulated by Angiotensin II. It interferes with 
extracellular matrix proliferation and synthesis.  
ENDOTHELIN-1:  
Endothelin-1 plays potential role in vasoconstriction as well as chemokine 
(Mitogen) of vascular smooth muscle cells. Endothelin 1is strongly associated with 
atherosclerosis formation. Oxidized LDL stimulates endothelin 1 synthesis and 
augments its vasoconstriction properties.  
ADHESION MOLECULES:  
Expression of ICAM-1 and VCAM-1 adhesion molecules are enhanced by 
Inflammation of endothelial injury. They bind with WBC and augment atherogenesis. 
In atherosclerosis VCAM-1 is more specific than ICAM.27 
            P-Selectin, is a receptor of platelet and endothelial cells. It adheres with  
vascular endothelial cells. It also a sign which shows that inflow of inflammatory 
cells into early as well as advanced atherosclerotic lesions.25 
L-Arginin is the precursor of nitric oxide which inhibits adhesion of monocytes 
to endothelial cells and alpha tocopherol (vitamin E). Adhesion is increased by 
androgen because it increases the  expression of VCAM-1. Antibodies against this 
will reduce the adhesion. 
 
 
18 
 
FLOW CHARACTERISTICS: 
Atheroma formation is often increased in bends, branches and bifurcations of 
blood vessel.  Because of the low shear stress it produces atherosclerosis. Altered 
blood flow disturbs the endothelial cell function and impair the protective functions.  
It is mainly due to  the release of  NO from the endothelial cells.16 
ANTI-OXIDIZED LDL ANTIBODIES  
Hydroperoxides produced by oxidation of fatty acid..  
                                                  Hydroperoxide 
 convert to active aldehydes like malondialdehyde. Malondialdehyde  
 lipoprotein become  more antigenic to the scavenger receptor on macrophage  
                               This oxidized LDL, becomes antigenic.31 
Antibodies are produced against the oxidized LDL.  
But these antibodies accumulate in the atheromatous plaques.  
When compared to chronic coronary condition the titre of these antibodies 
significantly rises within a month after an acute coronary syndrome. 
MITOCHONDRIAL DNA DAMAGE: 
                   Mitochondrial DNA damage produces development of atheroma which is 
proven experimentally in aortas of mice. Lesions in mDNA produces thin cap 
fibroma formation which is high risk in cardiovascular events. 
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GENETIC ASSOCIATIONS:  
  Atherosclerosis is polygenic. Environmental factors are important for the 
diseases  progression and manifestation. In atherosclerosis Polymorphisms of many 
genes play potential role in development of inflammation, thrombogenesis and 
derangements in lipid metabolism. 
 
INFECTION: 
  Long standing chronic infection has been found to increase the risk of 
atherosclerosis. Commonly encountered pathogens are herpes simplex virus (HSV) 
type 1 and type 2, Chlamydia Pneumoniae, Enterovirus (primarily Coxsackie B 
virus), hepatitis A virus (HAV), H .Pylori and Cytomegalovirus (CMV). 17  
Many mechanisms are involved in atherosclerosis genesis via chronic 
infectious state including  
1. Direct Endothelium Injury 
 2. Inducing a Systemic Inflammatory State.  
Not only infections, excess pathogenic burden itself a risk factor for 
atherosclerosis. Many studies showed that more than one pathogenic involvement 
directly correlated with the presence and severity of coronary disease .  
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IMPORTANCE OF PLAQUE RUPTURE: 
For symptomatic Atherosclerosis the lumen diameter should be reduced to at 
least 70%, until the patient will be asymptomatic. This happens when plaque is 
ruptured. When plaque ruptures lumen diameter gets narrowed and leads to 
symptoms pertaining to the end organ damage. 
ACS (myocardial infarction, unstable angina, stroke, and sudden death) are 
mainly due to plaque rupture and the silent plaque rupture and recurrent plaque 
ruptures followed by thrombosis formation shows advancement of atherosclerosis, 
associated  with an increase in plaque size and an increase blood vessel lumen  and a 
reduced arterial remodelling.    
 ACUTE MYOCARDIAL INFACRTION – AN OVERVIEW 
 INTRODUCTION: 
 DEFINITION 
                                Myocardial infarction (MI) is the irreversible necrosis and death 
of cardiac muscle due to diminished blood supply to the heart which leads to 
myocardial cell damage and ischemia supplied by that artery. It happens mainly due 
to prolonged ischemia23. The atheromatous plaque rupture followed by thrombus 
formation is the hallmark event to develop MI. 
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EPIDEMIOLOGY AND GLOBAL BURDEN 
                                Acute MI is one of the single largest killer of male and female . 
An American suffers a Ischemic heart disease [IHD] event every 29 seconds, and dies 
of one every minute. 47% of people having a IHD event will die from it that year. 
More than 4,50,000 people die each year from a IHD event without being 
hospitalized, most from cardiac arrest, 84% of IHD deaths are among people aged 
≥65 years and greater than 7 million have sustained a myocardial infarction. IHD is 
likely to become leading cause of death worldwide by 2020. Half of the death rate are 
reduced due to prompt diagnosis, treatment and life style modification. Global burden 
of diseases analysis showing there is shift from communicable diseases to non 
communicable diseases23. 
ETIOLOGY 
The following causes are important etiology for IHD development7 
1. Atherosclerotic plaque rupture with superimposed thrombus formation is the 
most common [95%] cause for MI 27 
2. Vasculitic syndromes 
3. Increased blood viscosity (e.g., Polycythemia Vera,  Thrombocytosis) 
4. Coronary embolism (e.g., from Endocarditis, Artificial heart valves) 
5. Congenital anomalies of the coronary arteries 
6. Severe coronary artery spasm (primary or cocaine-induced) 
7. Coronary trauma or aneurysm 
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8. Spontaneous coronary artery dissection 
9. Markedly increased myocardial oxygen demand (e.g., severe aortic stenosis) 
The above said are most common causes of acute myocardial infarction 
development. 
RISK FACTOR 
The presence of following any risk factor is associated with doubling the risk of an 
MI7,52. 
Major independent risk 
factors 
Predisposing risk 
factors 
Possible risk factors 
Hypertension 
Diabetes mellitus 
Cigarette smoking 
Elevated total and LDL            
cholesterol 
Low HDL cholesterol 
Older Age 
 
Obesity 
Physical inactivity 
Family history of 
premature Coronary 
diseases 
Psychosocial factors 
Ethnicity 
 
 
C-reactive protein 
Fibrinogen 
Elevated Lp(a) 
Homocysteine 
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                          European Society of Cardiology table of lifestyles and characteristics 
associated with an increased risk of a future coronary heart disease event.Resource: 
“Cardiology explained” 
AGE 
                Cardiovascular risk rises with advancing age. More than half of all heart 
attacks occur in persons over the age of 65, and 80 % of those who die of heart 
disease are in this age bracket.  You can’t turn back or stop the clock, but lifestyle 
factors—such as diet, exercise, and stress management—certainly minimize the 
adverse effects of advancing age7. 
GENDER 
                   Heart disease is by far the most common cause of death in both men and 
women, but there are important gender differences in risk, diagnosis, and treatment. 
This is mainly due to anatomy and hormones undoubtedly play important roles. For 
example, women have smaller coronary arteries than men—a consideration when 
treating coronary artery disease.  After menopause, women face an increasing risk of 
heart attack due to lack of estrogen production7. 
FAMILY HISTORY 
                           We’ve known for many decades that people with a strong family 
history of heart attacks, stroke, and other cardiovascular disorders face an increased 
risk of suffering similar fates. This has been amply demonstrated by the Framingham 
Heart Study and other large population studies. The risk is highest among those 
whose close relatives (sibling, parent, or grandparent) suffered a heart attack before 
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age fifty. There are some genes that increase cardiovascular risk. For example, some 
people inherit a gene that results in very high levels of LDL cholesterol, the bad form 
of this blood lipid, leading to early coronary artery disease11. 
RACE AND ETHNIC BACKGROUND 
                    Certain Racial or Ethnic groups have an especially high risk of heart 
disease. The highest risk groups are African Americans, Mexican Americans, Native 
Americans, native Hawaiians, and people from the Indian subcontinent. For example, 
African Americans tend to be highly salt-sensitive, which increases the risk of high 
blood pressure. Other factors that may play a role include unidentified genetic 
differences, diet, stress, low income, and limited access to health care7. 
ACQUIRED RISK FACTORS 
                   The list of acquired risk factors which can be modified or prevented are 
much larger than those that are beyond our control. Reducing or eliminating these 
risk factors is key role for achieving and maintaining heart healthy, so they deserve 
special attention. Elevated blood cholesterol and other lipids regardless of the 
underlying cause, can lead on to atherosclerosis, the buildup of fatty deposits (plaque) 
in the coronary arteries and the  other blood vessels7. 
ATHEROSCLEROSIS 
                  The following diagram clearly explain the relationship between 
atherosclerosis and arterial thrombus formation2, 3, 5. 
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HIGH BLOOD PRESSURE 
                   Often called the silent killer, high blood pressure produces no obvious 
symptoms until it reaches the advanced stage and damages organs, especially the 
kidneys, heart, brain, and blood vessels. It is one of the most common risk factors for 
heart attack, stroke, kidney failure, peripheral vascular disease, atherosclerosis, and 
heart failure11. 
METABOLIC SYNDROME 
                     Metabolic syndrome is a major health issues to develop heart attack. It 
has been recently found as a major cardiovascular risk factor. Diagnosis is based on a 
patients  having three or more of the following risk factors27: 
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 Abdominal Obesity (a waist circumference greater than 40 inches in a man and 
35 inches in a woman), 
  Elevated Triglycerides (>150 mg/dl ), low HDL cholesterol level 
  High Blood Pressure (more than 130/90), and Insulin Resistance 
 
DIABETES AND INSULIN RESISTANCE 
                        There is no doubt that persons with diabetes mellitus, both type I and 
type II, have an increased risk of heart attacks, stroke, and other cardiovascular 
diseases. Obesity Until recently, most people considered being overweight more a 
matter of aesthetics than a potentially deadly disease21,the greater the weight, the 
higher the risk of developing cardiac problem, high BP, Diabetes, and other major 
health issues. Obesity is defined as a body mass index (BMI) of 30 or higher—is now 
accepted as a leading cause of premature death. 
 
CIGARETTE SMOKING 
              Cigarette use is now recognized as the single most common cause of 
premature death in the United States and many other countries. Although most people 
know that smoking increases the risk of many forms of cancer, many are unaware of 
its role in cardiovascular disease, including sudden cardiac death, heart attacks, and 
strokes. Smoking also increases the risk to develop heart failure and circulatory 
disorders28.  
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STRESS 
            There is a lot of contraversies regarding relationship between stress and 
development of heartattack30.  
OTHER PSYCHOLOGICAL FACTORS 
                    Several studies supports that the depression is one among the risk factor 
to develop heart attack. Early diagnosis and treatment prevent heart attack.  
SEDENTARY LIFESTYLE 
                   Numerous studies have found that exercise is an important factor in 
preventing or treating heart disease37, the People who exercise regularly escapes from 
their cardiovascular morbidity and mortality. Not only live longer, but they also feel 
and look better. They are less likely to gain overweight, They also less likely to 
develop diabetes, high blood pressure, and elevated blood cholesterol. 
 
NEWLY IDENTIFIED RISK FACTORS 
FIBRINOGEN 
                   Fibrinogen is a component of blood that promotes the formation of blood 
clots, although it is essential for stopping bleeding from cuts and other wounds, high 
levels raise the risk of a heart attack—or a stroke if a clot were to block the essential 
flow of blood to the heart or brain10. Fibrinogen levels tend to rise with advancing 
age; smoking also promotes increased fibrinogen production, many experts believe 
this is one reason why smoking greatly increases cardiovascular risk7. 
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LIPOPROTEIN ( Lp(a)) 
                   It Increase the risk of coronary artery disease and heart attacks31. Lp (a) is 
the component of LDL (the carrier of the harmful type of cholesterol) that prevents 
blood clots from dissolving normally16. The Studies have shown that high levels of 
Lp (a) are perhaps more important risk factor to determine the heart attack than is 
high total cholesterol or low HDL cholesterol31. 
INFLAMMATION AND C-REACTIVE PROTEIN 
                    The high levels of C-reactive protein, or CRP, may be a risk factor even 
when a patient’s cholesterol is normal, because CRP is a protein in the blood that 
indicates inflammation somewhere in the body, and because chronic inflammatory 
disorders such as rheumatoid arthritis have been associated with major risk of cardiac 
problems18.19. The precise mechanism is unknown, but some have theorized that an 
underlying bacterial or viral infection may contribute to, or even cause, the buildup of 
fatty plaque along arterial walls52. 
               Inflammation in the arteries appears to promote the development of 
atherosclerosis and instability of the atherosclerotic plaque that can lead to formation 
of blood clots. 
HOMOCYSTEINE 
             Homocysteine is an amino acid that is a natural product of protein 
metabolism. Some people inherit a genetic defect that causes them to produce very 
high levels of homocysteine, putting them at a major risk to develop   atherosclerosis 
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and suffering an early heart attack. It is easily reduced with large doses of folic acid 
in some instances, other B vitamins are added to the regimen44. 
COCAINE USE 
           Cocaine use has led to an increase in high blood pressure, abnormal heart 
rhythms, angina, cardiomyopathy, and heart attacks among young people. During 
pregnancy, cocaine consumption   increases the risk of congenital heart defects. Even 
the first use of cocaine can lead to a cardiac crisis, heart attack, and even death. It 
reduces blood flow to the heart muscle by constricting the coronary arteries, which 
can result in a coronary artery spasm. At the same time, it speeds up the heart rate 
and increases blood pressure. As a result, the amount of oxygen reaching the heart 
muscle itself is reduced just when the heart muscle is demanding more oxygen7. 
PATHOGENESIS 
           Ischemia can develop whenever the blood flow stopped within 10 
seconds to longer than 20 minutes, which produce irreversible cell death. The 
death of myocardial cell starts from the Endocardium22, the area most distal to 
the arterial blood supply. Occlusion is typically seen in the proximal 2 cm of 
the LAD and left circumflex arteries and in the proximal and distal thirds of 
the RAD. 
• When the duration of blood flow occlusion prolonged, the cell death extending 
from the inner part of myocardium   to outer part of  Epicardium11. 
•  Three important  factors determine the severity of MI12 
30 
 
– Site of vessel wall occlusion 
– Duration of vessel wall  occlusion 
– Presence or absence of collateral circulation. 
– Depending upon the duration of vessel wall occlusion, the following 
changes happen in the myocardial cell. ATP depletion is the first 
changes noted in cell injury44. 
FEATURES DURATION 
Onset of ATP depletion Seconds 
Loss of contractility <2 Minutes 
ATP  reduced  
              to 50%  of  normal 
 
10 minutes 
               to 10%  of  normal 40 minutes 
Irreversible cell injury 20-40 minutes 
Microvascular injury > 1 hour  
ATP-Adenosine Triphosphate 
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MECHANISM OF BLOOD VESSEL OCCLUSION 
 Rupture of the lipid-rich atheromatous plaque, intraluminal thrombus, and 
intraplaque hemorrhage, are three pathological hallmarks most commonly 
recognized in the infarct-related coronary artery at the site of acuteMI15.  
 Platelet aggregation promoted by the platelet-derived mediators like   TXA2, 
serotonin, ADP, & PDGF that augment thrombosis and vasoconstriction. This 
is mainly due to diminished availability of naturally occurring endogenous 
substances that inhibit platelet aggregation, such as EDRF, tissue plasminogen 
activator, and PGI211, 12. 
 Platelets releases certain mediators which produce vasospasm of coronary 
blood vessels . 
  The coagulation pathway activated by tissue factor. 
 Thrombus occludes the lumen of vessel. 
 Ischemia without detection of coronary thrombosis due to vasculitis 
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VASOSPASM 
 
EMBOLI 
 
OTHERS 
 
 Intravascular 
Platelet 
aggregation 
 
 Drug ingestion (e.g., 
cocaine or ephedrine) 
 
 Vegetations of  
infective  
endocarditis, 
 
 Intracardiac 
prosthetic 
material 
• Vasculitis, 
• Hematologic 
abnormalities 
(e.g., sickle cell 
disease), 
• Amyloid 
deposition,  
• Vascular 
dissection, 
• Aortic stenosis,  
Lowered systemic 
blood pressure (e.g., 
shock) 
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CLASSIFICATION OF MI 
Anatomically MI sub classified into two types9 
 Transmural   and  Subendocardial infarction 
According to ECG finding it divided into two types 
 ST elevation (STEMI) and  Non  ST elevation  MI 
(NSTEMI) 
 
 TRANSMURAL INFARCTION-This infarction mainly due to complete 
occlusion of coronary artery which produce infarction of whole thickness of 
myocardial muscle supplied by that particular artery, otherwise called ST 
elevation MI (STEMI) 15. 
 SUBENDOCARDIAL INFARCTION–This infarction mainly involves small 
portion of the subendocardial region like a part of left ventricular wall, septum, 
or papillary muscles. 
SIGNS AND SYMPTOMS 
      According to a person signs and symptoms varies. A person may experience 
no symptoms to sudden death due to cardiac arrest41. Chest pain is the most 
common manifestation of MI. Patient may experience chest tightness, 
compression or squeezing type of pain which was not subsided by rest. Often pain 
radiate to left arm, back, shoulder and epigastric region. 
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 LEVINE'S SIGN: Localization of   chest pain by clenching the  fists 
over the sternum. 20-30% of patients are asymptomatic. They won’t 
experience chest pain, especially elderly patients, diabetes mellitus and 
hypertension.  
 Sudden onset of ischemia produces vasovagal reflex. 
 BREATHLESSNESS 
 During acute MI, left ventricular failure occurs. So patient may develop 
acute pulmonary edema. 
 Diaphoresis   
 Dizziness  
 Loss of consciousness (cerebral hypoperfusion and cardiogenic shock) 
 palpitation 
 Sudden cardiac arrest (due to ventricular fibrillation) 
 
KILLIP   CLASSIFICATION 
The patient prognosis is best assessed by killip classification. It classifies the  
heart failure in acute MI patient27.  
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CLASS 
 
DEFINITION 
 
30 DAY  
MORTALITY 
1 
11 
111 
1V 
No  S3 and Clear  lung 
S3 or crackles <50% of 
lung 
Crackles > 50% of  lungs 
Shock 
           5% 
          14% 
          32% 
         57% 
DIAGNOSIS 
PHYSICAL EXAMINATION 
 Patients usually presents with restless and in distress state41.  
 The periphery feel cold. 
 Dysnoea with abnormal auscultatory lung field like fine crackles, coarse 
crackles or rhonchi.  
 Hypertension related to anxiety or hypotension caused by cardiogenic shock.  
 The heart rate may vary from  bradycardia to tachycardia.  
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 On auscultation, s1 muffled due to reduced cardiac contractility. 
 Almost s4 heard in all mi patients. Whereas s3 detected only 10 to 20 
percentage of  patients.  
 Transient systolic murmurs  and  pericardial friction rub may be heard 
 Whereas in right ventricular infarcts, patient may develop distended jvp , 
peripheral  edema  and  high central venous pressure. 
DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION   BASED ON 
THREE     PARAMETERS 
     1. Clinical Symptoms 
     2. ECG Findings 
     3. Myocardial Enzymes and Protein Elevation (CPK-MB and Troponin I and T) 
ECG FINDINGS:  
1. ST segment elevation (Transmural infarct) or ST depression (subendocardial 
infarct)25, 26. 
2. T wave inversion and Q waves formation 
• ECG help us to identify location, size, time of infarction. 
PLASMA MARKERS OF MYOCARDIAL NECROSIS 
Myocardial dead cells releases the following enzymes and protein17,47. 
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MARKER RISE TIME PEAK TIME RETURN TO 
BASELINE 
Myoglobin 1   to  4 hours 6  to 7  hours  24  hours 
Troponin  I 3   to 12  hours 24  hours 5  to 10 days 
Troponin T 3  to  12  hours 12  to 48 hours 3  to  4 days 
Creatin kinase 4  to  8  hours 12  to  24  hours 3  to  4  days 
CK-MB 4 to  8  hours 18  to  36  hours 2  to  3  days 
AST 8  to  12  hours 18  to  36  hours 3  to  4  hours 
LDH 8  to  12  hours 3  to  6  days 8  to  14  days 
CK, Creatine kinase; AST, Aspartate Transaminase; LDH, Lactate Dehydragenase 
ADDITIONAL   INVESTIGATIONS: 
 Echocardiogram 
 Radionuclide Imaging 
 Stress Test 
 Coronary Angiography 
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TREATMENT 
     The patient’s complaints, history and  ECG are the first line of investigations  to 
diagnose acute  myocardial infarction27.  
 Once the diagnosis confirmed patient should be treated with following 
procedure. 
 Serial ECG and cardiac monitoring is important. 
 Should give adequate bed rest with nasal oxygen supplementation. 
 Administer loading dose of T.Aspirin 325 mg chewed. T.Clopidogrel 300mg. 
T.Atorvastatin 80mg. Give sublingual T. Nitroglycerin 5 -10 mg (if  SBP >90) 
 Chest pain may be relieved with morphine sulfate.  
PRIMARY CORONARY INTERVENTION (PCI): 
 Stenting PCI and angioplasty is the gold standard treatment of choice to restore 
coronary blood flow to ischemic myocardium46. 
 In this invasive procedure blocked coronary artery dilated. 
 The duration of symptoms to procedure must be within 2 hours to get excellent 
reperfusion.  
Before the PCI procedure, we have to administer T.Clopidogrel loading dose (300-
600 mg) or T.Ticagrelor 180 mg.  
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 Following one year after PCI procedure advise the patient to take dual 
antiplatelet drugs  with aspirin and clopidogrel or ticagrelor 
 Thrombolytic therapy 
 Thrombolytic drugs dissolve coronary blood clot  by converting plasminogen 
to plasmin.  
 The maximal benefit of thrombolysis is achieved when a person gets 
thrombolytic therapy within 3 hours of symptoms onset. 
 CONTRAINDICATION   TO   THROMBOLYTIC  THERAPY   
   The  Americans  College  of  Cardiology/ American Heart   Association 
(Acc/Aha)  And  By The European  Society  Of  Cardiology  (Esc)14
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TREATMENT
 
COR- Class of Recommendation;LOE, LOE-Level of Evidence; 
ACE INHIBITOR 
 Angiotensin-Converting Enzyme (ACE) inhibitors are given to patients 
who have an MI with cardiac failure in the absence of hypotension49. 
  It also help us to prevent from ventricular remodelling and preserve systolic 
ejection fraction. 
ANTICOAGULATION THERAPY 
 During percutaneous or surgical revascularization procedure, heparin is used  
as a thrombolytic therapy with alteplase49. 
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Patients presenting with  non–Q-wave MI, Low molecular weight heparin is the 
anticoagulant of choice. 
 
 
ACC-American College of Cardiolog,,AHA-American Heart Association, aPPT- 
activated partial thromboplastin time COR- Class of Recommendation. CrCl- 
creatinine clearance. IV- intravenous.LOE- Level of Evidence, N/A- not 
available,STEMI- ST segment elevation myocardial infarction, UFH- unfractionated 
heparin. 
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COMPLICATIONS 
VASCULAR COMPLICATIONS 
 Recurrent ischemia and infarction  
MECHANICAL COMPLICATIONS 
 Mitral Regurgitation 
 Cardiac  Rupture (Papillary muscle, left ventricular free wall andventricular 
septum) 
MYOCARDIAL COMPLICATIONS 
 Cardiac Failure 
 Dilatation Of Ventricular  Cavity  
 Systolic And Diastolic Dysfunction 
 Cardiogenic Shock 
 Right Ventricular Infarction 
 True Or False Aneurysm Formation  
PERICARDIAL COMPLICATIONS 
 Pericarditis And Pericardial Effusion 
 Dressler’s Syndrome 
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THROMBOEMBOLIC COMPLICATIONS 
 Left ventricular Mural thrombosis 
  Systemic  and  peripheral thromboembolism (Example- Stroke, DVT, 
pulmonary embolism etc) 
ELECTRICAL COMPLICATIONS 
 Ventricular tachycardia or ventricular  fibrillation 
  Tachyarrythmia  (ex-SVT)  or  bradyarrythmia (ex-Heart block) 
LIFE STYLE MODIFICATIONS 
                Life style modification is one of the most important primordial prevention 
from the myocardial infarction. It helps us  to  control the risk factors of  high blood 
cholesterol, diabetes mellitus and obesity, it also maintain normal  blood pressure27. 
Cessation of smoking and alcohol consumption: the risk of AMI 50% reduced, after 2 
year cessation of smoking.   
 Regular Physical activity  
 Daily Exercise 30 minutes. 
 Regular Exercise helps us to reduce blood cholesterol, diabetes 
mellitus, obesity and blood pressure. 
 
44 
 
DIET MODIFICATION 
 An Ideal Diet should be rich in vegetables, whole grains, fruits, 
and soluble fiber and low level of cholesterol and  saturated fatty 
acids . 
LIPID   MANAGEMENT 
 Consumption of   <200 mg/day of cholesterol and trans fatty  acids  
should advice ,along with saturated fatty acids less than 7% of total 
calories. 
 Per day 10 gram of viscous fiber, fish born omega -3 fatty acids and 2 
gram of plant sterols advisable limit50. 
 Instead of saturated fat, It should be replaced with rapeseed oil, olive oil 
to prevent excess cholesterol. 
 Even 10% of our current weight loss, greatly decrease cardiac risk. 
CONTROL AND MANAGEMENT OF COMORBID  DISEASES 
CONTROL OF HYPERTENSION AND DIABETES MELLITUS 
Patients with CAD should achieve the following goal to maintain their Blood 
pressure and glycaemic control. 
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 The blood pressure should be  maintained at < 130/80 mm Hg and the 
HbA1c in diabetic should be < 7% 
 Multimodal approach needs to attain our goal, this include Lifestyle 
changes, Diet plan  ,Physical activity  and  Medications. 
PATIENT   EDUCATION: 
Proper education of Entire community regarding heart attack signs and symptoms 
especially how to handle the situation of acute phase is important to avoid MI related 
morbidity and mortality49. 
The following health tips are useful to prevent heart attack in future 
 Regular Exercise 
 Healthy Food Habits 
 Quit  Smoking 
 Avoid Drinking 
PROLACTIN HORMONE 
 INTRODUCTION 
               In 1928 sticker discovered prolactin hormone. It is a polypeptide 
hormone secreted by lactotrophic cells of Anterior pituitary gland. It 
containing 198 AA (amino acid) and molecular weight of 22 kDa (kilodalton). 
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It located on Chromosome  6  and   half   life  of  20  to  30  minutes .The  milk 
secretion is important function of   Prolactin33. 
              Lactotrophs, desidual cells are main source of prolactin hormone. It 
mainly acts on breast, gonad and sex hormone. It excreted by liver and kidney. 
D2 receptor present in lactotrophs, dopamine act via this receptor and   inhibit 
prolactin secretion33 . 
According to size, it circulates three different forms: 
 Small molecular size ( 22kDa) 
 Big molecular size (50kDa) 
 Larger molecular size(100kDa) 
 80% of the hormones are biologically active, small molecular forms.  
FUNCTIONS OF PROLACTIN HORMONE 
 The Importance of Prolactin  is  initiation of  lactation34. 
 During  pregnancy ,along  with  Estrogen it  stimulate   breast  
development. 
 During  pregnancy ,it  suppress  the  secretion  of   FSH  and  LH which 
turn on to inhibit Ovulation. 
  Immune System  regulated  by T cell stimulation. 
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 t involve Osmoregulation which is transportation of  fluid,Ca,Na and Cl,  
across  intestinal epithelial membrane and helps to retain Na,K and Water in 
the kidney. 
 It involve the metabolism of fat cell synthesis,differentiation and regulation. 
 Excess prolactin lead on to dyslipidemia,increased platelete aggregation 
that promote on vascular thromosis which lead on to acute coronary 
syndrome. 
FACTORS  AFFECTING  SECRETION 
Factors  Increasing  Prolactin  
Secretion 
Factors  Decreasing  Prolactin    
Secretion 
 PRH-Prolactin releasing  hormone  
 Oxytocin - causes muscle 
contractions to expel milk. 
 Estrogen -during pregnancy ,it 
stimulates lactotropes to secrete 
prolactin. 
 TRH-Thyrotropin-releasing 
hormone  
 
 Excess Dopamine 
 Dopamine agonist like 
Bromocryptine 
 Head injury 
 Autoimmune disease 
 Growth hormone deficiency 
 Sheehan's  syndrome 
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          Anterior pituitary dysfunction causes decreased  prolactin secretion.most of 
the anterior pituitary hormones increases prolactin secreting  hormones35. 
REGULATION  OF  SECRETION 
 
 
 
 
 
 
 
 
 VIP-Vasoactive intestinal peptide  
 Stress and Breast feeding 
 Sleep and chest wall trauma 
  Dopamine antagonist drugs like 
antipsychatric drugs 
 Infection(e.g.histoplasmosis,T
uberculosis) 
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 Stimulation of Prolactin secretion mainly comes under Breast feeding action. 
Which is Triggered by PRH(prolactin releasing hormone) ,inhibited by 
Dopamine a prolactin inhibitory hormone(PIH)33. 
  PIH level  predominates in male.  
 In females, according to  blood estrogen , prolctin level varies.; 
-PIH  secretion , increased in low level of  blood  estrogen. 
 -PRH secretion, increased in high level of  blood estrogen. 
SYMPTOMS  OF   HYPOPROLACTINEMIA   AND   
HYPERPROLACTINEMIA 
HYPOPROLACTINEMIA HYPERPROLACTINEMIA 
 
 Ovarian Diseases 
 Impotence  
 Delayed Puberty 
 Abnormal Spermatogenesis. 
 Infertility 
 
 
Women: 
Amenorrhoea  And  Oligomenorrhoea 
GalactorrhoeaAnd  Infertility 
HirsutimAnd  Osteoporosis 
Men(Late Onset): 
Gynaecomastia  And Impotence. 
Osteoporosis 
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DIAGNOSIS: 
 Detailed History  including medications, menstrual cycle35 
 Local  Examination (  galactorrhoea) 
LABORATORY 
  Measurement of  serum Prolactin level 
 Thyroid function test 
 LH and FSH assay 
 Pregnancy teST 
IMAGING MODALITY 
 MRI scan  is the best image of choice.it detect very minimal lesion even 3 to 
5mm size 
 High speed helical- CT  scan also  very useful. 
TREATMENT: 
MEDICAL  AND SURGICAL MANAGEMENT 
HYPERPROLACTINOMA   MANAGEMENT   GUIDE 
 Dopamine agonist :Bromocriptine,Lisuride,Quinagolide,Cabergoline35. 
 Large pituitary tumour treated with surgical removal or radiation  therapy 
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If needed,  replacement of  thyroid hormone or other hormonal replacement  therapy 
like estrogen and progestins in ovarian insufficiency is adviced. 
AIM AND OBJECTIVES  
 
 Aim of the present study was evaluation of the serum prolactin level in the 
acute myocardial infarction (MI) regarding the current 
 Pharmacotherapy in management of MI. 
 To compare the levels of serum prolactin in patients with acute myocardial                       
infarction and normal population, to know the role of current 
pharmacotherapy.  
 To compare Serum Prolactin with  Serum Troponin I . 
MATERIALS AND METHODS 
Method of collection of clinical sample and data-Patients admitted in the CCU, 
dept.of cardiology,Govt Stanley Hospital  with Acute myocardial infarction shall be 
studied. 
STUDY DESIGN: 
 CASE CONTROL STUDY. 
STUDY PERIOD: 
March 2017 to October 2017 [ 8 month ] 
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CASE DEFINITION:  
Myocardial infarction (MI) is the irreversible necrosis and death of cardiac muscle 
due to diminished blood supply to the heart which leads to myocardial cell damage 
and ischemia supplied by that artery. The diagnosis of acute myocardial infarction  
based clinically ,electro and  Echocardiographically. 
INCLUSION CRITERIA: 
Patients with acute ST elevation changes in ECG and hypokinesia of reginal wall 
motion abnormality in Echocardiographically. 
EXCLUSION CRITERIA: 
1. Hypothyroidism Patients.  
2. Chronic dopamine agonist drug intaker 
3.  3.Smoker 
SAMPLE SIZE : 
 50 
METHODOLOGY:  
 The Acute MI patients are subjected to a detailed history and clinical 
examination with the help of  ECG and ECHO.  
 Detailed Past history of drug intake like T.Metformin, T.Aspirin, 
T.Clopidogrel, T.Metoprolol, T,Atorvastatin and T,Isosorbidedinitrate. 
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 The Acute MI patients are divided into 50 subjects in one group, with healthy 
controls as second group.  
 The subjects of each group are appropriately matched for age and sex. 
 Basic investigations with serum prolactin and serum troponin are taken within 
24 hours onset of symptoms. 
 The serum prolactin levels of the two  groups are then compared.  
 The serum prolcatin levels are compared with serum troponin among the acute 
MI  patients. 
 T.Metformin.T.Aspirin, combined T.aspirin and T.Clopidogrel and other drugs 
like T.Atorvasatin,T.Metoprolol,T.ISDN compared with paitents and control 
group 
 TABLE : 
PATIENTS GROUP and CONTROL GROUP 
Age Sex 
Serum 
Prolactin 
Serum 
Troponin 
I 
T. 
Aspirin 
T.Aspirin 
and 
T.Clopidogrel 
T.Metformin 
Other 
Drugs 
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REFERENCE VALUE 
 Serum Prolactin Normal Range - Male less than 15ng/dl. 
                                                      Female less than 20ng/dl. 
    Serum Troponin  I  Normal Range-Both Sex Less than 50ng/L.  
The Normal Population Is Selected From Patients Attending Master Health Check 
Up. 
METHOD USED FOR ESTIMATION OF SERUM PROLACTIN  :  
ELISA kit method 
METHOD USED FOR ESTIMATION OF SERUM TROPONIN I: 
ELISA kit method 
RESULTS AND DISCUSSION 
STATISTICALANALYSIS 
           Descriptive statistics was done for all data and suitable statistical tests of 
comparison were done. Continuous variables were analyzed with the Unpaired t test 
and Single factor ANOVA and categorical variables were analyzed with Fisher Exact 
Test. correlation analysis was done using persons r.   Statistical significance was 
taken as P < 0.05. The data was analyzed using SPSS Version 16. Microsoft Excel 
2010.was used to generate charts 
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Study Groups 
 
 
Study Groups 
Normal 
Prolactin 
High Prolactin Controls 
Number 23 26 49 
Percentage 23.47 26.53 50.00 
 
 
23
26
49
23.47
26.53
50.00
0
10
20
30
40
50
60
Normal Prolactin High Prolactin Controls
Study Groups
Number Percentage
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Age  
 
 
Age 
Groups 
Normal 
Prolactin 
% 
High 
Prolactin 
% Controls % 
≤ 50 years 2 8.70 1 3.85 7 14.29 
51-60 years 10 43.48 9 34.62 19 38.78 
61-70 years 11 47.83 11 42.31 16 32.65 
71-80 years 0 0.00 5 19.23 7 14.29 
Total 23 100.00 26 100.00 49 100.00 
 
2
10
11
0
1
9
11
5
7
19
16
7
0
2
4
6
8
10
12
14
16
18
20
≤ 50 years 51-60 years 61-70 years 71-80 years
Age Groups
Normal Prolactin High Prolactin Controls
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Age Distribution 
Normal 
Prolactin 
High Prolactin Controls 
Mean 58.61 61.65 59.86 
SD 6.18 7.39 8.35 
P value  
Single Factor ANOVA Test 
0.3732 
Majority of the normal prolactin group patients belonged to 61-70 years age class  
interval (n=11, 47.83%) with a mean age of 58.61 years. In the high prolactin group 
patients, majority belonged to 61-70 years age class interval (n=11, 42.31%) with a 
mean age of 61.65 years. In the control group patients, majority belonged to 51-60 
years class interval (n=19, 38.78%) with a mean age of 59.86 years.  
The association between the study groups and age distribution is considered to be not 
statistically significant since p > 0.05 as per single factor ANOVA test. 
Gender 
 
13
10
18
8
32
17
0
5
10
15
20
25
30
35
Male Female
Gender Status
Normal Prolactin High Prolactin Controls
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Gender 
Status 
Normal 
Prolactin 
% 
High 
Prolactin 
% Controls % 
Male 13 56.52 18 69.23 32 65.31 
Female 10 43.48 8 30.77 17 34.69 
Total 23 100.00 26 100.00 49 100.00 
P value  
Chi Squared Test 
0.6373 
Majority of the study subjects were males in normal prolactin group patients (n=13, 
56,52%), high prolactin group patients (n=18, 69.23%) and control group patients 
(n=32, 65.31%), The association between the study groups and gender status is 
considered to be not statistically significant since p > 0.05 as per chi squared 
test.BMI
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BMI 
Groups 
Normal 
Prolactin 
% 
High 
Prolactin 
% Controls % 
Normal 0 0.00 0 0.00 29 59.18 
Overweight 19 82.61 21 80.77 20 40.82 
Obese 4 17.39 5 19.23 0 0.00 
Total 23 100.00 26 100.00 49 100.00 
 
BMI Distribution 
Normal 
Prolactin 
High Prolactin Controls 
Mean 26.40 28.43 24.25 
SD 1.91 1.66 1.68 
P value  
Single Factor ANOVA Test 
<0.0001 
Majority of the normal prolactin group patients belonged to overweight BMI class 
interval (n=19, 82.61%) with a mean BMI of 28.40. In the high prolactin group 
patients, majority belonged to overweight BMI class interval (n=21, 80.77%) with a 
mean BMI of 28.43. In the control group patients, majority belonged to normal BMI 
class interval (n=29, 59.18%) with a mean BMI of 24.25.  
The association between the study groups and BMI distribution is considered to be 
statistically significant since p < 0.05 as per single factor ANOVA test. 
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DISCUSSION  
The mean BMI levels were significantly elevated in high prolactin group compared to 
control group by a mean difference of 4.19(15% higher).  
The mean BMI levels were significantly elevated in normal prolactin group 
compared to control group by a mean difference of 2.15(8% higher) 
The mean BMI levels were significantly elevated in high prolactin group compared to 
normal prolactin group by a mean difference of 2.03(7% higher) 
This difference is significant with a p-value <0.0001 as per single factor ANOVA 
test.  
CONCLUSION  
In this study we can safely conclude that high and normal prolactin group had 
significantly higher levels of BMI compared to control group and high prolactin 
group had significantly higher levels of BMI compared to normal prolactin group 
among acute MI patients.  
In conclusion, we observed that higher serum prolactin concentrations is associated 
acute MI patients with elevated BMI  
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FBS 
 
 
Fasting Blood 
Sugar Groups 
Normal 
Prolactin 
% 
High 
Prolactin 
% Controls % 
≤ 80 mg/dl 1 4.35 0 0.00 1 2.04 
81-100 mg/dl 10 43.48 7 26.92 22 44.90 
101-120 mg/dl 6 26.09 10 38.46 21 42.86 
121-140 mg/dl 1 4.35 2 7.69 5 10.20 
>140 mg/dl 5 21.74 7 26.92 0 0.00 
Total 23 100.00 26 100.00 49 100.00 
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Age Distribution 
Normal 
Prolactin 
High Prolactin Controls 
Mean 118.30 121.27 102.80 
SD 40.95 31.99 12.48 
P value  
Single Factor ANOVA Test 
0.0092 
 
Majority of the normal prolactin group patients belonged to 81-100 mg/dl FBS class 
interval (n=10, 43.48%) with a mean FBS of 118.30 mg/dl. In the high prolactin 
group patients, majority belonged to 101-120 mg/dl FBS class interval (n=10, 
38.46%) with a mean FBS of 121.27 mg/dl. In the control group patients, majority 
belonged to 81-100 mg/dlFBS class interval (n=22, 44.90%) with a mean FBS of 
102.80 mg/dl.  
The association between the study groups and FBS distribution is considered to be 
statistically significant since p < 0.05 as per single factor ANOVA test. 
DISCUSSION  
The mean FBS levels were significantly elevated in high prolactin group compared to 
control group by a mean difference of 18.47(15% higher).  
The mean FBS levels were significantly elevated in normal prolactin group compared 
to control group by a mean difference of 15.51(13% higher) 
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The mean FBS levels were significantly elevated in high prolactin group compared to 
normal prolactin group by a mean difference of 2.96(2% higher) 
This difference is significant with a p-value 0.0092 as per single factor ANOVA test.  
CONCLUSION  
In this study we can safely conclude that high and normal prolactin group had 
significantly elevated levels of FBS compared to control group and high prolactin 
group had significantly elevated levels of FBS compared to normal prolactin group 
among acute MI patients.  
In conclusion, we observed that higher serum prolactin concentrations is associated 
acute MI patients with elevated FBS  
SBP 
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Systolic Blood 
Pressure 
Groups 
Normal 
Prolactin 
% 
High 
Prolactin 
% Controls % 
≤ 110 mm Hg 5 21.74 1 3.85 25 51.02 
111-130 mm Hg 8 34.78 2 7.69 16 32.65 
131-150 mm Hg 7 30.43 15 57.69 7 14.29 
151-170 mm Hg 3 13.04 8 30.77 1 2.04 
Total 23 100.00 26 100.00 49 100.00 
 
Systolic Blood 
Pressure Distribution 
Normal 
Prolactin 
High Prolactin Controls 
Mean 132.61 147.69 118.35 
SD 16.57 14.51 15.16 
P value  
Single Factor ANOVA Test 
<0.0001 
Majority of the normal prolactin group patients belonged to 111-130 mm Hg SBP 
class interval (n=8, 34.78%) with a mean SBP of 132.61.mm Hg. In the high 
prolactin group patients, majority belonged to 131-150 mm Hg SBP class interval 
(n=15, 57.69%) with a mean SBP of 147.69 mm Hg. In the control group patients, 
majority belonged to ≤ 110 mmHg SBP class interval (n=25, 51.02%) with a mean 
SBP of 118.35 mm Hg.  
65 
 
The association between the study groups and SBP distribution is considered to be 
statistically significant since p < 0.05 as per single factor ANOVA test. 
DISCUSSION  
The mean SBP levels were significantly elevated in high prolactin group compared to 
control group by a mean difference of 29.35(20% higher).  
The mean SBP levels were significantly elevated in normal prolactin group compared 
to control group by a mean difference of 14.26(11% higher) 
The mean SBP levels were significantly elevated in high prolactin group compared to 
normal prolactin group by a mean difference of 15.08(10% higher) 
This difference is significant with a p-value <0.0001 as per single factor ANOVA 
test.  
CONCLUSION  
In this study we can safely conclude that high and normal prolactin group had 
significantly elevated levels of SBP compared to control group and high prolactin 
group had significantly elevated levels of SBP compared to normal prolactin group 
among acute MI patients.  
In conclusion, we observed that higher serum prolactin concentrations is associated 
acute MI patients with elevated SBP 
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DBP 
 
 
Diastolic 
Blood 
Pressure 
Groups 
Normal 
Prolactin 
% 
High 
Prolactin 
% Controls % 
≤ 170 mmHg 6 26.09 2 7.69 28 57.14 
71-80 mm Hg 6 26.09 2 7.69 15 30.61 
81-90 mm Hg 9 39.13 14 53.85 4 8.16 
91-100 mm Hg 2 8.70 8 30.77 2 4.08 
Total 23 100.00 26 100.00 49 100.00 
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Diastolic Blood 
Pressure Distribution 
Normal 
Prolactin 
High Prolactin Controls 
Mean 83.04 90.77 73.67 
SD 9.74 8.45 10.55 
P value  
Single Factor ANOVA Test 
<0.0001 
Majority of the normal prolactin group patients belonged to 81-90 mm Hg DBP class 
interval (n=9, 39.13%) with a mean DBP of 83.04.mm Hg. In the high prolactin 
group patients, majority belonged to 81-90 mm Hg DBP class interval (n=14, 
53.85%) with a mean DBP of 90.77 mm Hg. In the control group patients, majority 
belonged to ≤ 170 mmHg DBP class interval (n=28, 57.14%) with a mean DBP of 
74.67 mm Hg.  
The association between the study groups and DBP distribution is considered to be 
statistically significant since p < 0.05 as per single factor ANOVA test. 
DISCUSSION  
The mean DBP levels were significantly elevated in high prolactin group compared 
to control group by a mean difference of 17.10(19% higher).  
The mean DBP levels were significantly elevated in normal prolactin group 
compared to control group by a mean difference of 9.37(11% higher)  
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The mean DBP levels were significantly elevated in high prolactin group compared 
to normal prolactin group by a mean difference of 7.73(9% higher) 
This difference is significant with a p-value <0.0001 as per single factor ANOVA 
test.  
CONCLUSION  
In this study we can safely conclude that high and normal prolactin group had 
significantly elevated levels of DBP compared to control group and high prolactin 
group had significantly elevated levels of DBP compared to normal prolactin group 
among acute MI patients.  
In conclusion, we observed that higher serum prolactin concentrations is associated 
acute MI patients with elevated DBP 
TROPONIN I 
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Troponin I 
Groups 
Normal 
Prolactin 
% 
High 
Prolactin 
% Controls % 
≤ 50 ng/mL 0 0.00 0 0.00 49 100.00 
51-70 ng/mL 5 21.74 0 0.00 0 0.00 
71-90 ng/mL 12 52.17 6 23.08 0 0.00 
91-110 ng/mL 5 21.74 17 65.38 0 0.00 
111-130 
ng/Ml 
1 4.35 3 11.54 0 0.00 
Total 23 100.00 26 100.00 49 100.00 
 
Troponin I 
Distribution 
Normal 
Prolactin 
High Prolactin Controls 
Mean 81.96 95.65 17.16 
SD 14.77 9.27 5.95 
P value  
Single Factor ANOVA Test 
<0.0001 
Majority of the normal prolactin group patients belonged to 71-90 ng/mL troponin I 
class interval (n=12, 52.17%) with a mean troponin I of 83.04. ng/mL. In the high 
prolactin group patients, majority belonged to 91-110 ng/mL troponin I class interval 
(n=17, 65.38%) with a mean troponin I of 90.77 ng/mL. In the control group patients, 
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majority belonged to ≤ 50 ng/mL troponin I class interval (n=49, 100%) with a mean 
troponin I of 74.67 ng/mL.  
The association between the study groups and troponin I distribution is considered to 
be statistically significant since p < 0.05 as per single factor ANOVA test. 
DISCUSSION  
The mean troponin Ilevels were significantly elevated in high prolactin group 
compared to control group by a mean difference of 78.49(82% higher).  
The mean troponin Ilevels were significantly elevated in normal prolactin group 
compared to control group by a mean difference of 64.79(79% higher) 
The mean troponin Ilevels were significantly elevated in high prolactin group 
compared to normal prolactin group by a mean difference of 13.70(14% higher) 
This difference is significant with a p-value<0.0001 as per single factor ANOVA test.  
CONCLUSION  
In this study we can safely conclude that high and normal prolactin group had 
significantly elevated levels of troponin I compared to control group and high 
prolactin group had significantly elevated levels of troponin I compared to normal 
prolactin group among acute MI patients.  
In conclusion, we observed that higher serum prolactin concentrations is associated 
acute MI patients with elevated troponin I. 
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TGL 
 
 
Triglyceride 
Groups 
Normal 
Prolactin 
% 
High 
Prolactin 
% Controls % 
≤ 130 mg/dl 12 52.17 0 0.00 34 69.39 
131-150 mg/dl 6 26.09 3 11.54 13 26.53 
151-170 mg/dl 3 13.04 7 26.92 1 2.04 
171-190 mg/dl 2 8.70 13 50.00 1 2.04 
191-210 mg/dl 0 0.00 3 11.54 0 0.00 
Total 23 100.00 26 100.00 49 100.00 
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Triglyceride 
Distribution 
Normal 
Prolactin 
High Prolactin Controls 
Mean 134.96 172.65 121.94 
SD 20.79 17.80 18.06 
P value  
Single Factor ANOVA Test 
<0.0001 
Majority of the normal prolactin group patients belonged to ≤ 130 mg/dl triglyceride 
class interval (n=12, 52.17%) with a mean triglyceride of 134.96. mg/dl. In the high 
prolactin group patients, majority belonged to 171-190 mg/dl triglyceride class 
interval (n=13, 50%) with a mean triglyceride of 172.65 mg/dl. In the control group 
patients, majority belonged to ≤ 130 mg/dl triglyceride class interval (n=34, 69.39%) 
with a mean triglyceride of 121.94 mg/dl.  
The association between the study groups and triglyceride distribution is considered 
to be statistically significant since p < 0.05 as per single factor ANOVA test. 
DISCUSSION  
The mean triglyceride levels were significantly elevated in high prolactin group 
compared to control group by a mean difference of 50.72(29% higher).  
The mean triglyceride levels were significantly elevated in normal prolactin group 
compared to control group by a mean difference of 13.02(10% higher) 
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The mean triglyceride levels were significantly elevated in high prolactin group 
compared to normal prolactin group by a mean difference of 37.70(22% higher) 
This difference is significant with a p-value < 0.0001 as per single factor ANOVA 
test.  
CONCLUSION  
In this study we can safely conclude that high and normal prolactin group had 
significantly elevated levels of triglyceride compared to control group and high 
prolactin group had significantly elevated levels of triglyceride compared to normal 
prolactin group among acute MI patients.  
In conclusion, we observed that higher serum prolactin concentrations is associated 
acute MI patients with elevated triglyceride 
CHOLESTEROL  
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Total 
Cholesterol 
Groups 
Normal 
Prolactin 
% 
High 
Prolactin 
% Controls % 
≤ 150 mg/dl 6 26.09 0 0.00 19 38.78 
151-200 mg/dl 12 52.17 5 19.23 27 55.10 
201-250 mg/dl 4 17.39 15 57.69 3 6.12 
251-300 mg/dl 1 4.35 6 23.08 0 0.00 
Total 23 100.00 26 100.00 49 100.00 
 
Total Cholesterol 
Distribution 
Normal 
Prolactin 
High Prolactin Controls 
Mean 174.13 217.96 161.22 
SD 34.33 29.56 21.24 
P value  
Single Factor ANOVA Test 
<0.0001 
Majority of the normal prolactin group patients belonged to 151-200 mg/dl 
cholesterol class interval (n=12, 52.17%) with a mean cholesterol of 174.13. mg/dl. 
In the high prolactin group patients, majority belonged to 201-250 mg/dl cholesterol 
class interval (n=15, 57.59%) with a mean cholesterol of 217.96 mg/dl. In the control 
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group patients, majority belonged to ≤ 150 mg/dl cholesterol class interval (n=19, 
38.78%) with a mean cholesterol of 161.22 mg/dl.  
The association between the study groups and cholesterol distribution is considered 
to be statistically significant since p < 0.05 as per single factor ANOVA test. 
DISCUSSION  
The mean cholesterol levels were significantly elevated in high prolactin group 
compared to control group by a mean difference of 56.74(26% higher).  
The mean cholesterol levels were significantly elevated in normal prolactin group 
compared to control group by a mean difference of 12.91(7% higher) 
The mean cholesterol levels were significantly elevated in high prolactin group 
compared to normal prolactin group by a mean difference of 43.83(20% higher) 
This difference is significant with a p-value <0.0001as per single factor ANOVA test.  
CONCLUSION  
In this study we can safely conclude that high and normal prolactin group had 
significantly elevated levels of cholesterol compared to control group and high 
prolactin group had significantly elevated levels of cholesterol compared to normal 
prolactin group among acute MI patients.  
In conclusion, we observed that higher serum prolactin concentrations is associated 
acute MI patients with elevated cholesterol 
76 
 
METFORMIN  
 
 
 
Tab. 
Metformin 
Normal 
Prolactin 
% 
High 
Prolactin 
% Controls % 
Yes 8 34.78 1 3.85 19 38.78 
No 15 65.22 25 96.15 30 61.22 
Total 23 100.00 26 100.00 49 100.00 
P value 
Chi Squared Test 
<0.0001 
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The study subjects on treatment with metformin is 34.78%, 3,85% and 38.78% in 
normal prolactin group, high prolactin group and control group patients respectively. 
The association between the study groups and metformin intake status is considered 
to be statistically significant since p < 0.05 as per chi squared test. 
DISCUSSION  
The incidence of metformin intake is significantly decreased in high prolactin group 
compared to control group by a percentage difference of 34.93(90% lower).  
The incidence of metformin intake is significantly decreased in normal prolactin 
group compared to control group by a percentage difference of 3.99(10% lower).  
The incidence of metformin intake is significantly decreased in high prolactin group 
compared to normal prolactin l group by a percentage difference of 30.94(89% 
lower).  
CONCLUSION  
In this study we can safely conclude that high and normal prolactin group had 
significantly decreased incidence of metformin intake compared to control group and 
high prolactin group had significantly decreased incidence of metformin intake 
compared to normal prolactin group among acute MI patients.  
In conclusion, we observed that higher serum prolactin concentrations is associated 
acute MI patients with decreased incidence of metformin intake 
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ASPIRIN  
 
 
Tab. 
Aspirin 
Normal 
Prolactin 
% 
High 
Prolactin 
% Controls % 
Yes 7 30.43 14 53.85 10 20.41 
No 16 69.57 12 46.15 39 79.59 
Total 23 100.00 26 100.00 49 100.00 
P value 
Chi Squared Test 
<0.0001 
 
The study subjects on treatment with asprin are 30.43%, 53.85% and 20.41% in 
normal prolactin group, high prolactin group and control group patients respectively. 
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The association between the study groups and asprin intake status is considered to be 
statistically significant since p < 0.05 as per chi squared test. 
DISCUSSION  
The incidence of asprin intake is significantly decreased in high prolactin group 
compared to control group by a percentage difference of 33.44(62% higher).  
The incidence of asprin intake is significantly decreased in normal prolactin group 
compared to control group by a percentage difference of 10.03(33% higher).  
The incidence of asprin intake is significantly decreased in high prolactin group 
compared to normal prolactin l group by a percentage difference of 23.41(43% 
higher).  
CONCLUSION  
In this study we can safely conclude that high and normal prolactin group had 
significantly increased incidence of asprin intakecompared to control group and high 
prolactin group had significantly increased incidence of asprin intakecompared to 
normal prolactin group among acute MI patients.  
In conclusion, we observed that higher serum prolactin concentrations is associated 
acute MI patients with increased incidence of asprin intake 
  
80 
 
ASPIRIN AND CLOPIDOGREL 
 
 
Tab. 
Aspirin 
and Tab. 
Clopidogrel 
Normal 
Prolactin 
% 
High 
Prolactin 
% Controls % 
Yes 2 8.70 9 34.62 9 18.37 
No 21 91.30 17 65.38 40 81.63 
Total 23 100.00 26 100.00 49 100.00 
P value 
Chi Squared Test 
0.0711 
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The study subjects on treatment with aspirin and clopidogrel are 8.70%, 32.46% and 
18.37% in normal prolactin group, high prolactin group and control group patients 
respectively. 
The association between the study groups and aspirin and clopidogrel intake status is 
considered to be not statistically significant since p > 0.05 as per chi squared test. 
METOPROLOL / ATORVASTATIN / ISOSORBIDE DINITRATE 
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Tab.Metoprolol / 
Tab.Atorvastati
n / 
Tab.Isosorbide 
Dinitrate 
Normal 
Prolactin 
% 
High 
Prolacti
n 
% 
Control
s 
% 
Yes 5 21.74 2 7.69 13 26.53 
No 18 78.26 24 92.31 36 73.47 
Total 23 100.00 26 100.00 49 100.00 
P value 
Chi Squared Test 
0.0342 
 
The study subjects on treatment with Metoprolol / Atorvastatin / Isosorbide Dinitrate 
are 21.74%, 7.69% and 20.41% in normal prolactin group, high prolactin group and 
control group patients respectively. 
The association between the study groups and Metoprolol / Atorvastatin / Isosorbide 
Dinitrate intake status is considered to be statistically significant since p < 0.05 as per 
chi squared test. 
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DISCUSSION  
The incidence of Metoprolol / Atorvastatin / Isosorbide Dinitrate intake is 
significantly decreased in high prolactin group compared to control group by a 
percentage difference of 18.84(71% lower).  
The incidence of Metoprolol / Atorvastatin / Isosorbide Dinitrate intake is 
significantly decreased in normal prolactin group compared to control group by a 
percentage difference of 4.79(18% lower).  
The incidence of Metoprolol / Atorvastatin / Isosorbide Dinitrate intake is 
significantly decreased in high prolactin group compared to normal prolactin l group 
by a percentage difference of 14.05(65% lower).  
CONCLUSION  
In this study we can safely conclude that high and normal prolactin group had 
significantly decreased incidence of Metoprolol / Atorvastatin / Isosorbide Dinitrate 
intakecompared to control group and high prolactin group had significantly decreased 
incidence of Metoprolol / Atorvastatin / Isosorbide Dinitrate intakecompared to 
normal prolactin group among acute MI patients.  
In conclusion, we observed that higher serum prolactin concentrations is associated 
acute MI patients with decreased incidence of Metoprolol / Atorvastatin / Isosorbide 
Dinitrate intake. 
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CORRELATION - SERUM PROLACTIN VS SERUM TROPONIN I 
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The relationship in values between serum prolactin levels and serum troponin I levels 
is statistically significant as the p value is  <0.0001 with a string and positive 
correlation as per pearson’s coefficient of 0.73 
The linear increase in serum prolactin levels in relation to increased serum troponin I 
levels is true 73% of times. But out of the 58% only 53% of the variation in mean 
increased serum troponin I 
Serum prolactin levels can be predicted from the relationship serum troponin I 
levels. For every 1 unit increase in serum prolactin levels there is a corresponding 0.2 
unit serum prolactin levels.  
GENDER DIFFERENCES IN SERUM PROLACTIN LEVEL 
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Gender Differences in Serum Prolactin 
Level 
Serum Prolactin 
Serum 
Troponin I 
Male 
Mean 13.73 52.41 
SD -10.72 -37.27 
Female 
Mean 16.08 54.60 
SD 10.45 39.09 
P value  
Unpaired t Test 
<0.0001 >0.9999 
The mean prolactin values in males was 13.73 and in females was 16.08. The 
association between the gender status and serum prolactin distribution is considered 
to be statistically significant since p < 0.05 as per unpaired t test. 
The mean troponin I values in males was 52.41 and in females was 54.60. The 
association between the gender status and serum prolactin distribution is considered 
to be not statistically significant since p > 0.05 as per unpaired t test. 
DISCUSSION  
The mean prolactin levels were significantly elevated in female group compared to 
male group by a mean difference of 2.36(84% higher).  
CONCLUSION  
In this study we can safely conclude that high prolactin group are significantly 
associated with gender (more in women acute MI patients.)  
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DIFFERENTIAL EFFECTS OF TREATMENTS ON SERUM PROLACTIN 
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Differential 
Effects of 
Treatments on 
Serum Prolactin 
Control 
Treated 
With Tab. 
Metformi
n 
Treate
d With 
Tab. 
Aspirin 
Treated 
With Tab. 
Aspirin 
and Tab. 
Clopidogr
e 
Treated With 
Tab.Metoprolol 
/ 
Tab.Atorvastati
n / 
Tab.Isosorbide 
Dinitrate 
Treated 
Mean 0.00 8.95 21.27 18.94 10.27 
SD 0.00 4.19 10.99 12.95 7.82 
Not 
Treated 
Mean 7.80 16.60 12.15 13.45 15.96 
SD 2.54 11.51 9.46 9.73 11.08 
P value  
Unpaired t Test 
0.0014 0.0001 0.0385 0.0218 
 
The mean prolactin values in treated subjects was 8.95, 21.27, 18.59 and 10.27 in 
metformin, aspirin, aspirin and clopidogre and metoprolol / tab.atorvastatin / 
tab.isosorbide dinitrate groups. Similarly mean prolactin values in not treated subjects 
was 7.80, 16.00, 12.15 and 15.56 in metformin, aspirin, aspirin and clopidogre and 
metoprolol / tab.atorvastatin / tab.isosorbide dinitrate groups. The association 
between the treatment groups and serum prolactin distribution is considered to be 
statistically significant since p < 0.05 as per unpaired t test. 
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DISCUSSION  
The mean prolactin levels were significantly decreased in metformin treatment group 
compared to no treatment group by a mean difference of 7.65(46% lower).  
The mean prolactin levels were significantly elevated in asprin treatment group 
compared to no treatment group by a mean difference of 9.12(46% lower).  
The mean prolactin levels were significantly elevated in metformin treatment group 
compared to male group by a mean difference of 7.65(43% higher).  
The mean prolactin levels were significantly elevated in asprin treatment group 
compared to male group by a mean difference of 5.49(29% higher).  
The mean prolactin levels were significantly elevated in metoprolol / tab.atorvastatin 
/ tab.isosorbide dinitrate treatment group compared to male group by a mean 
difference of 5.69(36% higher). .  
CONCLUSION  
In this study we can safely conclude that high prolactin group are significantly 
associated with increased intake of aspirin and metoprolol / tab.atorvastatin / 
tab.isosorbide dinitrte treatment group 
In this study we can also safely conclude that high prolactin group are significantly 
associated with decreased intake of aspirin and metoprolol / tab.atorvastatin / 
tab.isosorbide dinitrate treatment group. 
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Differential Effects of Treatments on Serum Troponin I 
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Differential 
Effects of 
Treatments on 
Serum Troponin 
I 
Control 
Treated 
With Tab. 
Metformi
n 
Treate
d With 
Tab. 
Aspirin 
Treated 
With Tab. 
Aspirin 
and Tab. 
Clopidogr
e 
Treated With 
Tab.Metoprolol 
/ 
Tab.Atorvastati
n / 
Tab.Isosorbide 
Dinitrate 
Treated 
Mean 
 
48.96 66.73 57.80 49.17 
SD 
 
35.71 40.44 37.96 36.13 
Not 
Treated 
Mean 17.16 54.72 48.31 52.01 54.50 
SD 5.95 38.57 35.76 37.84 38.39 
P value  
Unpaired t Test 
0.5075 0.0321 0.5434 0.5502 
 
The mean troponin I values in treated subjects was 48.96, 66.54, 57.89 and 49.17 in 
metformin, aspirin, aspirin and clopidogre and metoprolol / tab.atorvastatin / 
tab.isosorbide dinitrate groups. Similarly mean troponin I values in not treated 
subjects was 54.72, 48.31, 37.83 and 54.50 in metformin, aspirin, aspirin and 
clopidogre and metoprolol / tab.atorvastatin / tab.isosorbide dinitrate groups. The 
association between the treatment groups and serum troponin Idistribution is 
considered to be statistically not significant since p > 0.05 as per unpaired t test. 
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OVERALL CONCLUSION 
 The association between the study groups and age distribution is considered to 
be not statistically significant. 
 Serum Prolactin level higher among acute myocardial infarction patients. 
 Prolactin is associated with a comprehensive panel of incident cardiovascular 
disease risk factors. Measurement of circulating prolactin levels on a routine 
basis among high risk individuals is more likely to provide substantial insight 
into cardiometabolic risk. 
 Elevation of Serum Prolactin level  is associated with a chronic inflammatory 
state  
 T.Metformin treated group patients showed significantly reduced serum 
prolactin level in acute MI patient compared to control group. 
 T.aspirin treated group patients showed significantly high Serum Prolactin 
level in Acute MI patient compared to control group,this is mainly due to 
aspirin increases prostaglandin generation in hypothalamic region which 
stimulate high serum prolactin. 
 Serum Prolactin was not affected by T.Clopidogrel. 
 Other drugs like T.Metoprolol, T.Atorvastatin, T.ISDN shows reduced Serum 
Prolactin level. 
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                                                  SUMMARY  
This study “EVALUATION OF SERUM PROLACTIN LEVELS INACUTE 
MYOCARDIAL INFARCTION: THE ROLE OFPHARMACOTHERAPY”  was 
carried out in government Stanley medical college and hospital , Chennai  from 
March 2017 to October 2017 
 50 Acute MI   patients were selected and their serum prolactin levels and 
serum troponin  levels were studied correlated with  50 normal healthy 
individuals.the  role  of pharmacotherapy in serum prolactin level was 
assessed. 
 In acute MI patient showed significant elevation of serum prolactin level. 
 According to various pharmacotherapy  drugs like Metformin decreases the 
serum prolactin,Aspirin increases the serum prolactin and other drugs like 
Clopidogrel no effect.  
 So serum prolactin level increased in acute MI reflects underlying 
cardiovascular complications. 
LIMITATIONS 
1. Low sample size. So little space for robust statistical analysis. 
2. Study population restricted to patients referred for acute MI to our department, 
so a selection may have influenced the results. 
3. Poor financial support 
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4. Inability to use research design like  cohort study due to paucity of time and 
resources 
AREAS FOR FUTURE RESEARCH: 
1. Prospective studies are needed to further study the association between Serum 
Prolactin , Atherosclerosis and Acute Myocardial Infarction. 
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                                                   PROFORMA  
 
NAME:                                             AGE:     SEX: 
ADDRESS:                                        CONTACT NO: 
OCCUPATION   :  
COMPLAINTS: 
 
PAST H/O 
     CARDIAC ILLNESS            1. Yes  2. No  If yes specify_________  
     DIABETIC ILLNESS             1.Yes         2. No If  yes specify 
 
PERSONAL H/O: 
 
H/O SMOKING: 
 
FAMILY HISTORY: 
RELEVANT CLINICAL EXAMINATION 
BP:            PR:                   RR:                BMI: 
CVS:                                            RS:           
PA: 
 
CNS: 
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INVESTIGATIONS: 
COMPLETE BLOOD COUNT: 
 ECG: 
FBS: 
SERUM TROPONIN I: 
SERUM PROLACTIN: 
ECHO: 
RENAL FUNCTION TEST: 
SERUM ELECTROLYTES: 
LIVER FUNCTION TEST: 
FASTING LIPID PROFILE: 
 
COURSE OF PRESENT ILLNESS: 
 
 
COMPLICATIONS : 
 
COMMENT: 
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                GOVT. STANLEY MEDICAL COLLEGE, CHENNAI – 600001 
INFORMED CONSENT 
 
             “EVALUATION OF SERUM PROLACTIN LEVEL IN ACUTE 
MYOCARDIAL  INFARCTION :ROLE OF  PHARMACOTHERAPY ” 
AT GOVERNMENT STANLEY MEDICAL COLLEGE AND HOSPITAL, 
CHENNAI. 
 
Place of study:  Govt. Stanley medical college, Chennai 
 
 
I ……………………………………………. have been informed about the details of 
the study in my own language. 
I have completely understood the details of the study. 
I am aware of the possible risks and benefits, while taking part in the study. 
I agree to collect samples of blood/saliva/urine/tissue if study needs. 
I understand that I can withdraw from the study at any point of time and even then, I 
can receive the medical treatment as usual. 
I understand that I will not get any money for taking part in the study. 
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I will not object if the results of this study are getting published in any medical 
journal, provided my personal identity is not revealed. 
I know what I am supposed to do by taking part in this study and I assure that I would 
extend my full cooperation for this study.   
  
 
 Volunteer:       Witness: 
Name and address        Name and address  
Signature/thumb impression:     Signature/thumb 
impression 
Date:        Date: 
  
Investigator Signature and date 
 
 
 
                  GOVT. STANLEY MEDICAL COLLEGE, CHENNAI – 600001 
INFORMED CONSENT 
    “EVALUATION OF SERUM PROLACTIN LEVELS IN ACUTE 
MYOCARDIAL INFARCTION: THE ROLE OF  PHARMACOTHERAPY” 
 
நான் இந்த ஆராய்ச்சியில் விவரங்களை முற்றிலும் புாிந்து 
ககாண்டேன். ஆய்வில் பங்கு எடுத்து டபாது, சாத்தியமான அபாயங்கள் 
மற்றும் பயன்களை பற்றி நான் அறிந்துள்டைன். 
நான் எந்தகவாரு டவளையிலும் ஆய்வில் இருந்து திரும்ப முடியும், 
அதன்பின்னர், நான்வழக்கம்டபால் மருத்துவ சிகிச்ளச கபறமுடியும் என்று 
புாிந்து ககாள்கிடறன். 
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நான் ஆய்வில் பங்குஎடுத்து பணம் எளதயும் கபற முடியாது என்று 
அறிந்துள்டைன். இந்த ஆய்வின் முடிவுகள் எந்தகமடிக்கல் ஜர்னலில் 
கவைியிேப்பே இருந்தால் நான் எதிர்க்கவில்ளை, என்தனிப்பட்ே 
அளேயாைத்ளத கவைிப்படுத்தப்பட்டு இருக்ககூோது. 
நான் இந்த ஆய்வில் பங்ககடுப்பதன் மூைம் நான் என்ன கசய்ய 
டபாகிடறன் என்று கதாியும். நான் இந்த ஆய்வில் என் முழு 
ஒத்துளழப்ளபயும் ககாடுப்டபன் என்று உறுதியைிக்கிடறன். 
தன்னார்வைர்       சாட்சி  
கபயர்மற்றும்முகவாி   கபயர்மற்றும்முகவாி 
ளககயாப்பம்  /விரல்டரளக:   ளககயாப்பம் / விரல்டரளக: 
 
 
ஆராய்ச்சியாைராக 
ளககயாப்பம்மற்றும்டதத 
 
 
 
 
MASTER CHART 
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A
G
E 
S
E
X 
BMI 
FB
S 
BP 
Sr.
Pro
lact
in 
Sr.t
rop
oni
n I 
Tri
glyc
erid
e 
Tota
l 
chol
estro
l 
T.Me
tfor
min 
T.As
pirin 
T.As
pirin 
and 
T. 
Clop
idog
rel 
T.Me
top,T
.Ator
v,T.I
SDN 
56 M 31 201 140/90 
10.4
8 
72 142 184 YES NO NO NO 
63 M 29 103 120/80 12.7 102 153 187 NO YES NO YES 
50 M 27 184 160/100 31 112 184 207 NO YES NO NO 
52 F 25.3 121 140/90 12 78 127 162 NO NO NO YES 
48 M 28 197 110/70 8 67 134 157 YES NO NO NO 
57 F 28.4 104 150/90 29 98 188 204 NO YES NO NO 
66 M 31 169 130/90 11 61 124 147 NO NO YES NO 
67 F 27.8 94 110/70 13 76 178 212 YES NO NO NO 
53 M 32 108 140/90 36 109 183 247 NO NO YES NO 
62 M 27 
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s 
180/100 39 92 172 203 NO NO YES NO 
52 F 28.5 96 150/90 19 84 168 221 NO NO NO YES 
72 M 29 182 160/100 42 97 132 167 NO YES NO NO 
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61 F 27.8 112 140/90 10 89 143 154 NO NO NO YES 
65 M 27.5 101 150/90 33 93 155 172 NO YES NO NO 
49 M 28.5 205 160/100 7 79 128 178 YES NO NO NO 
64 F 26.2 98 130/80 11 88 119 152 YES NO NO NO 
59 M 29.5 104 110/70 6 65 123 148 NO NO YES NO 
51 F 28.6 106 130/80 9 74 152 203 YES NO NO YES 
66 M 27 100 110/70 7 62 119 143 NO NO NO YES 
61 M 31 173 140/90 32 104 182 219 NO YES NO NO 
52 M 28.5 91 150/90 12 87 124 128 NO NO NO NO 
57 M 32.5 102 130/90 8 102 132 122 YES NO NO YES 
63 F 29 185 160/90 13 71 102 159 YES NO NO NO 
71 M 27.4 101 140/90 21 92 172 234 YES NO NO NO 
59 M 26.4 93 120/70 9 76 111 196 YES NO NO NO 
62 M 26.6 86 110/70 5 69 131 149 NO NO NO YES 
58 F 29 154 150/90 35.4 101 187 253 NO NO YES NO 
61 F 28 87 140/90 18 98 122 273 NO YES NO NO 
52 M 27.6 84 130/80 9 108 138 162 NO NO NO YES 
72 M 28.5 102 150/100 29 99 176 217 NO YES NO NO 
64 F 26.4 109 160/100 16 112 187 209 YES NO NO NO 
54 M 31 97 140/90 28 95 162 212 NO YES NO NO 
69 F 27.6 142 170/100 37 111 183 264 NO NO YES NO 
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68 F 32.6 79 140/80 14 91 123 186 YES NO NO NO 
52 F 31 94 160/90 39.5 87 168 205 NO YES NO NO 
65 M 29 126 170/100 27 79 175 254 NO NO NO YES 
73 M 28.6 178 160/100 28 113 183 237 NO YES NO NO 
55 F 28.5 86 140/90 36.6 92 156 251 NO NO YES NO 
56 M 27.4 99 130/80 7 74 124 173 YES NO NO NO 
51 M 25.5 110 140/90 17 86 141 186 NO NO YES NO 
65 M 27 113 150/90 22 97 164 208 NO YES NO NO 
63 F 30 169 170/100 24 86 156 182 NO YES NO NO 
71 M 28 121 130/90 31.8 79 142 175 NO NO YES NO 
64 M 29 119 150/90 28 95 197 253 NO YES NO NO 
51 M 28 91 110/70 35.2 94 168 203 NO YES NO NO 
62 M 27.5 97 140/80 26 85 198 209 NO NO YES NO 
67 F 26 94 120/70 38.6 98 185 212 NO NO NO YES 
65 F 29.8 85 140/80 28 102 179 217 NO NO YES NO 
55 M 26 116 150/90 24 91 201 276 NO YES NO NO 
 
 
 
 
ABBREVIATIONS 
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              SMC-Smooth Muscle Cell 
              ECM-Extra Cellular Matrix 
              ICAM-Intracellular Adhesion 
              TNF-Tumour Necrosis Factor 
              MI-Myocardial Infarction 
              IL-Interleukin 
              PAPP-A-Pregnancy Associated Plasma Protein 
              EDRF-Endothelin Releasing Factor 
              PGI-Prostaglandin I 
              TXA2-Thromboxin A2 
               AMI-Acute Myocardial Infarction 
          ISDN-Isosorbide Dinitrate 
          DVT-Deep Vein Thrombosis 
          MMP-Matrix Metalloproteinase 
          IHD-Ishaemic Heart Disease 
          ACE-Angiotensin Converting Enzyme 
